Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Year of publication
Document Type
- Journal article (21)
Language
- English (21) (remove)
Keywords
- multiple myeloma (6)
- PET (5)
- positron emission tomography (5)
- medicine (3)
- molecular imaging (3)
- 18F-FDG PET/CT (2)
- CXCR4 (2)
- FDG (2)
- isotopes (2)
- radionuclide therapy (2)
- theranostics (2)
- 11C-Methionine PET/CT (1)
- 18FDG-PET/CT (1)
- 5IA-SPECT (1)
- 68Ga-DOTATATE (1)
- 68Ga-Pentixafor PET/CT (1)
- Antibodies (1)
- Atherosclerotic plaque (1)
- Carbon-11 (1)
- Cardiovascular risk factors (1)
- DOPA-responsive-dystonia (1)
- FDG-PET/CT (1)
- GCH1 (1)
- GPR54 (1)
- IBA-1 (1)
- KISS1 receptor (1)
- KISS1-54 (1)
- MRI (1)
- Macrophage (1)
- Matlab (1)
- Medizin (1)
- Multiple myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- PET/CT (1)
- PRRT (1)
- Parkinson disease (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Positron emission tomography (1)
- SAH (1)
- Somatostatin receptor (1)
- TBI (1)
- TSPO (1)
- [\(^{68}\)]KISS1-54 (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- autoradiography (1)
- biosynthesis (1)
- bone disease (1)
- bone marrow cells (1)
- brain (1)
- cancer treatment (1)
- carboxylation (1)
- cell staining (1)
- cholinergic activity (1)
- cognitive decline (1)
- data analysis (1)
- diffuse (1)
- dopamine (1)
- dopamine acetylcholine (1)
- esophagogastric junction (1)
- exome sequencing (1)
- experience (1)
- focal (1)
- glioblastoma multiforme (1)
- glioma (1)
- health care (1)
- human tumor cell lines (1)
- imaging techniques (1)
- immunohistochemistry (1)
- immunostaining (1)
- isotopic labelling (1)
- kisspeptin (1)
- lesions (1)
- levodopa-induced dyskinesia (1)
- macrophages (1)
- magnetic resonance imaging (1)
- management (1)
- metabolic tumor volume (MTV) (1)
- metabolism (1)
- methionine (1)
- methylation (1)
- microglial cells (1)
- neuroinflammation (1)
- nicotinic receptors (1)
- pattern (1)
- peptide receptor (1)
- photons (1)
- preclinical imaging (1)
- progression (1)
- radiochemistry (1)
- radiogenomics (1)
- radiopharmaceuticals (1)
- relapse (1)
- sarcoidosis (1)
- signal to noise ratio (1)
- smoldering myeloma (1)
- somatostatin (1)
- somatostatin receptors (1)
- stem-cell transplantation (1)
- super ultraviolet (1)
- thyroid carcinomas (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- treatment response (1)
- weight drop (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (19)
- Medizinische Klinik und Poliklinik II (8)
- Neurologische Klinik und Poliklinik (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Neurochirurgische Klinik und Poliklinik (2)
- Institut für Experimentelle Biomedizin (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Klinik und Poliklinik für Strahlentherapie (1)
- Pathologisches Institut (1)
- Physiologisches Institut (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 680966 (1)
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.
Methods:
We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.
Results:
PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.
Conclusion:
Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.